Can Heterogenic Patterns of JAK2, MPL, and CALR Genes Predict Specific Clinical Characteristics of Myeloproliferative Disorders?

Morsali, Measam; Mehrab Mohseni, Mahdieh; Naseroleslami, Maryam

doi:10.22034/pmj.2023.2007881.1008

Document Type : Original Article

Authors

¹ Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

² Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, &lrm;Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

https://doi.org/10.22034/pmj.2023.2007881.1008

Abstract

Myeloproliferative neoplasm (MPN) is a neoplasm with three categories; essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) and it usually is diagnosed through mutation analysis in several essential genes; JAK2, MPL, CALR. The mutations of mentioned genes in 50 patients with MPN and 50 healthy volunteers were determined via allele-specific PCR and sequencing. Based on the results, MPN and its subtypes have significant relation with mutations (p<0.05). JAK2 (exon 14) mutation was related to MPN and its subtypes except for ET and CALR (exon 9) type 1 was merely related to ET, but CALR (exon 9) type 2 mutation was more prevalent in MPN and PV (p<0.05). None of the mutations co-occurred simultaneously. There was no evidence of mutation in JAK2 (exon 12) and MPL (exon 9 and 10) in our study, so they are unsuitable diagnostic candidates. So, mutations in JAK2 (exon 14), and CALR (exon 9) type 1 and 2 are essential in MPN diagnosis in Iranians.

Keywords

20.1001.1.24765538.2023.8.31.1.2

Main Subjects

Personalized Medicine

References

1.Lanzarone G, Olivi M. The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms. Medicina. 2021;57(8):813. [DOI: 10.3390/medicina57080813].

2.Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-9.

3.Lasho T, Finke C, Hanson C, Jimma T, Knudson R, Ketterling R, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2012;26(5):1135-7.

4.Killick SB, Wiseman DH, Quek L, Cargo C, Culligan D, Enright H, et al. British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes. British Journal of Haematology. 2021;194(2):282-93.

5.Grinfeld J, Nangalia J, Baxter E, Wedge D, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379:1416-30.

6.Ok CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, et al. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology. 2021;34(1):20-31.

7.Bruneau J, Molina TJ. WHO classification of tumors of hematopoietic and lymphoid tissues. Hematopathology. 2020:501-5.

8.Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, The Journal of the American Society of Hematology. 2014;124(7):1062-9.

9.Wong WJ, Hasserjian RP, Pinkus GS, Breyfogle LJ, Mullally A, Pozdnyakova O. JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica. 2018;103(2):e63.

10.Scott LM. The JAK2 exon 12 mutations: a comprehensive review. American journal of hematology. 2011;86(8):668-76.

11.Wong R, Sun S, Wang H-Y, Broome HE, Murray S, Thorson J. In Frame Calr Exon 9 Mutations: Often Ignored but Potentially Significant. Blood. 2018;132:5480.

12.Zulkeflee RH, Zulkafli Z, Johan MF, Husin A, Islam MA, Hassan R. Clinical and laboratory features of JAK2 V617F, CALR, and MPL Mutations in Malaysian patients with classical myeloproliferative neoplasm (MPN). International journal of environmental research and public health. 2021;18(14):7582.

13.Heppner J, Nguyen LT, Guo M, Naugler C, Rashid-Kolvear F. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada. BMC research notes. 2019;12(1):1-5.

14.Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. Journal of hematology & oncology. 2016;9(1):1-11.

15.Yassin MA, Taher A, Mathews V, Hou H-A, Shamsi T, Tuglular T, et al. Myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria: epidemiological indices and treatment practice patterns from the multinational, multicenter, observational MERGE registry. Blood. 2018;132:5461.

16.Ashorobi D, Gohari P. Essential thrombocytosis. StatPearls [Internet]. 2021.

17.Belcic Mikic T, Pajic T, Sever M. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms. Scientific reports. 2019;9(1):1-9.

18.Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Young Ok C, Salim AA, Routbort MJ, et al. Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic features. American journal of clinical pathology. 2016;145(3):418-27.

19.Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, et al. The Prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1–negative myeloproliferative neoplasms. American journal of clinical pathology. 2015;144(1):165-71.

20.Kim BH, Cho Y-U, Bae M-H, Jang S, Seo E-J, Chi H-S, et al. JAK2 V617F, MPL, and CALR mutations in Korean patients with essential thrombocythemia and primary myelofibrosis. Journal of Korean medical science. 2015;30(7):882-8.

21.Lieu C-H, Shen Y-J, Lai W-C, Tsai W-H, Hsu H-C. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms. Journal of the Chinese Medical Association. 2010;73(10):530-2.

22.Akpinar T, Hançer V, Nalçaci M, Diz-Küçükkaya R. Kronik miyeloproliferatif neoplazmlarda MPL W515L/K mutasyonlari. Turk J Hematol. 2013;30:8-12.

23.Shams SF, Ayatollahi H, Sadeghian MH, Afzalaghaee M, Shakeri S, Yazdandoust E, et al. Prevalence of MPL (W515K/L) mutations in patients with negative-JAK2 (V617F) myeloproliferative neoplasm in North-East of Iran. Iranian journal of pathology. 2018;13(4):397.

24.Rabade N, Subramanian P, Kodgule R, Raval G, Joshi S, Chaudhary S, et al. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. Indian Journal of Pathology and Microbiology. 2018;61(2):209.

25.Xia D, Hasserjian RP. Molecular testing for JAK 2, MPL, and CALR in myeloproliferative neoplasms. American Journal of Hematology. 2016;91(12):1277-80.

Personalized Medicine Journal

Can Heterogenic Patterns of JAK2, MPL, and CALR Genes Predict Specific Clinical Characteristics of Myeloproliferative Disorders?

References

References

Volume 8, Issue 31
original article
December 2023
Pages 1-9

Can Heterogenic Patterns of JAK2, MPL, and CALR Genes Predict Specific Clinical Characteristics of Myeloproliferative Disorders?

References

References

Volume 8, Issue 31 original articleDecember 2023Pages 1-9

Volume 8, Issue 31
original article
December 2023
Pages 1-9